Aveo releases final OS data on tivozanib; Ablynx reports success for PhII RA study;

 @FierceBiotech: In case you missed it: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib. Article | Follow @JohnCFierce

@RyanMFierce: J&J's Alzheimer's R&D chief sticks by 'golden age' prediction after bapi bust. But where's the data? More | Follow @RyanMFierce

> Aveo ($AVEO) and Astellas reported final OS results for tivozanib's Phase III. Investigators are blaming a one-sided crossover for the fact that the OS data on the experimental drug failed to match the OS rate for Nexavar. The therapy hit the endpoint on progression-free survival. Release

> Belgium's Ablynx says it is recording positive results in a Phase II study of a new rheumatoid arthritis therapy. Release

> Peregrine ($PPHM) reports that in a Phase II study patients treated with a combination of bavituximab and gemcitabine had a 28% tumor response rate as compared to 13% in the control arm. Median OS, the primary endpoint of the trial, was 5.6 months for the bavituximab plus gemcitabine arm and 5.2 months for the control arm. Release

Pharma News

@FiercePharma: Sanofi plans to boost Lantus production in Ireland with a $59 million upgrade to Waterford site. More | Follow @FiercePharma

@EricPFierce: 2012 M&A was slow in biopharma as cos. choked down previous mega mergers. Execs may be ready to tango in 2013. Special Report | Follow @EricPFierce

@AlisonBFierce: The WHO granted PharmaJet's Stratis Needle-free Injector performance, quality and safety pre-qualification status. Release | Follow @AlisonBFierce

> U.K. gatekeepers shut out Novartis cancer treatment. News

> Discount program robs pharma to pay hospitals, report claims. Story

Medical Device News

 @FierceMedDev: Attorneys: JNJ knew of mesh problems before marketing. Article | Follow @FierceMedDev

 @MarkHFierce: Medtronic won FDA approval for its next-gen Advisa MRI-friendly pacemaker. Release | Follow @MarkHFierce

 @DamianFierce: More regulatory struggles for St. Jude as it recalls a component of its Amplatzer heart plug. Story | Follow @DamianFierce

> J&J metal hip trial stirs up renewed call for 510(k) reform. Item

> Dako inks companion diagnostics deal with Pfizer. Article

Drug Delivery News

> Alnylam joins Spanish team to deliver successful RNAi. Story

> Genelux, Sloan-Kettering test delivery of mesothelioma drug. More

> Germany grants reimbursement for Delcath's chemo delivery tech. Item

> UCLA team snuffs cancer cells with nanoshell delivery. News

> Smiths Medical wins FDA clearance for 'smart' infusion pump. Report

And Finally… Investigators at the University of Pennsylvania vet school say they found a new pathway to stimulate bone growth, and the discovery could be useful both for humans as well as animals. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.